ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer
| dc.contributor.author | Madry, R. | |
| dc.contributor.author | Fujiwara, K. | |
| dc.contributor.author | Vergote, I. B. | |
| dc.contributor.author | Sehouli, J. | |
| dc.contributor.author | Salutari, V. | |
| dc.contributor.author | Zola, P. | |
| dc.contributor.author | Wenham, R. M. | |
| dc.contributor.author | Korach, J. | |
| dc.contributor.author | Pautier, P. | |
| dc.contributor.author | Cibula, D. | |
| dc.contributor.author | Lheureux, S. | |
| dc.contributor.author | Hasegawa, K. | |
| dc.contributor.author | Kim, B-G. | |
| dc.contributor.author | Lai, C-H. | |
| dc.contributor.author | Gonzalez-Martinez, A. | |
| dc.contributor.author | Liu, Q. | |
| dc.contributor.author | Keefe, S. M. | |
| dc.contributor.author | Puglisi, M. | |
| dc.contributor.author | TOPUZ, Samet | |
| dc.date.accessioned | 2022-02-18T10:12:42Z | |
| dc.date.available | 2022-02-18T10:12:42Z | |
| dc.identifier.citation | Fujiwara K., Vergote I. B. , Sehouli J., Salutari V., Zola P., Madry R., Wenham R. M. , Korach J., Pautier P., Cibula D., et al., "ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer", European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, cilt.30 | |
| dc.identifier.other | av_868a78fc-884c-45c8-9d78-047ab3dc2377 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/178802 | |
| dc.language.iso | eng | |
| dc.subject | Health Sciences | |
| dc.subject | Oncology | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.title | ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer | |
| dc.type | Bildiri | |
| dc.contributor.department | Saitama Medical School , , | |
| dc.identifier.volume | 30 | |
| dc.contributor.firstauthorID | 3387600 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]
